📰 Open Angle Glaucoma News
Page 3 - Open Angle Glaucoma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Open Angle Glaucoma. Real-time updates on events, politics, business and more.
May 4, 2022
The Chronic Pulmonary Hypertension market size is anticipated to surge owing to extensive research and development activities of pharmaceutical companies, along with the launch of various multiple-stage
April 11, 2022
Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma - read this article along with other careers information, tips and advice on BioSpace
March 12, 2022
The Ghana Optometry Association (GOA) has called for a review of the eye care policy for glaucoma to reduce its high prevalence in the country. The GOA noted that the Ministry of Health must lead in ensuring that the needed glaucoma management policy was put in place to encourage all…
January 18, 2022
Glaucoma Medications Market: The innovation of new Technology along with the increasing cases of Glaucoma worldwide and development of new drugs is expecte
January 18, 2022
Glaucoma Medications Market: The innovation of new Technology along with the increasing cases of Glaucoma worldwide and development of new drugs is expecte
July 2, 2021
Efforts to understand more about the magnitude and distribution of glaucoma in Africa have usually been limited by reliance on clinic populations and inadequate definitions of glaucoma. Nonetheless, the surveys indicate that OAG is an important cause of blindness in Africa. The early stages of both types of glaucoma are often asymptomatic so patients often present late, particularly in developing countries. The challenges are with late presentation for diverse reasons one of which is low awaren...
May 14, 2021
Sun Pharma Advanced Research Company today reported positive top-line results from its Phase 3 trial (CLR_16_33) for its investigational drug, PDP-716 ophthalmic suspension, for the treatment of Open Angle Glaucoma or Ocular Hypertension. The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day. PDP-716 is a novel, once daily, ophthalmic suspension of Brimonidine Tartrate 0.35%. PDP-716 is developed usin...
May 7, 2021
Glioblastoma Pipeline Analysis: 60+ Key Pipeline Therapies and 60+ Key Pharma Players are Looking Out in the Glioblastoma Pipeline Landscape iCrowd Newswire DelveInsights Glioblastoma Pipeline Insight report offers a detailed overview of the pipeline therapies that are in various clinical and preclinical stages of growth, as well as their launch and how the market is expected to change as a result across the Glioblastoma domain. For Glioblastoma emerging drugs, the Glioblastoma Pipeline Analysi...
March 6, 2021
Opthalmologists in Hyderabad to observe Glaucoma Week from today
February 14, 2021
Punch Newspapers Sections Lara Adejoro Vice-President, Ophthalmological Society of Nigeria and Consultant Ophthalmologist at The Eye Doctors Clinic, Dr. Abiola Oyeleye, says some glaucoma eye drops can ‘minimally increase’ the incidence of sexual dysfunction and impotence. He, however, added that the benefits of the eye drops far outweigh the consideration of not using them. Oyeleye spoke in reaction to a study published by the National Centre for Biotechnology Information on the correlatio...